Arbutus

Arbutus to Participate in September Investor Conferences

Retrieved on: 
Tuesday, September 6, 2022
RNA interference, HBV, RNA, Program, Arbutus, Virology, Coronavirus, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, Hepatitis B virus, GLOBE, PD, Conference, Nasdaq, Immune system, Therapy, Company, Investor, Webcast, Drug discovery, Patient, Vaccine

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.

Key Points: 
  • Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.
  • Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses.
  • We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening.
  • We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2).

Arbutus Biopharma Announces Issuance of a New Key U.S. Patent Related to AB-729

Retrieved on: 
Tuesday, August 30, 2022
RNA interference, Liver cancer, CFBV, COVID-19, N-Acetylgalactosamine, HBV, RNA, Securities Exchange Act of 1934, Cirrhosis, Program, Membrane protein, Hepatocyte, Hepatitis B virus, Securities Act of 1933, Arbutus, Patent, Virology, Vaccine, Death, USPTO, Coronavirus, Risk, Hepatitis B, World Health Organization, Antigen, Goal, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, GLOBE, PD, Nasdaq, Immune system, Therapy, NA, Conditional sentence, World, Drug discovery, Annual report, Forward-looking statement, Patient, Pharmaceutical industry

11,427,823, which provides composition of matter patent protection for Arbutus AB-729 RNAi therapeutic product.

Key Points: 
  • 11,427,823, which provides composition of matter patent protection for Arbutus AB-729 RNAi therapeutic product.
  • The patent is expected to provide Arbutus with exclusivity for AB-729 out to at least April 2038.
  • Furthermore, AB-729 has shown achievement of virologic control in five cHBV patients after discontinuing treatment with AB-729 and nucleos(t)ide analog (NA)-therapy.
  • Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Tuesday, August 9, 2022
U.S. Securities and Exchange Commission, GLOBE, SEC, Cancer, Security (finance), Knowledge, Annual report, Patient, Nivolumab, G&A, Infection, HBsAg, Immune system, HPV, Prostate cancer, EASL, Private Securities Litigation Reform Act, Degenerative disease, Oxford University Innovation, VTP, Licensure, Safety, Hepatitis B, Investigational New Drug, OUI, University, Hepatitis, Autoimmunity, HBV, MERS, COVID-19, Program, Vaccine, ChAdOx1, AstraZeneca, Arbutus, Vaccitech, IND, MVA, Company, Human papillomavirus infection, NASDAQ, Research, Insurance, Antigen, EMA, Pharmaceutical industry, Renewable energy

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.
  • Second Quarter 2022 Financial Highlights:
    Cash position: As of June 30, 2022, cash and cash equivalents were $192.3 million, compared to $214.1 million as of December 31, 2021.
  • Revenues: Revenues were $17.1 million in the second quarter of 2022 compared to $15.0 million in the first quarter of 2022.
  • Research and development expenses: Research and development expenses were $9.7 million in the second quarter of 2022 compared to $10.7 million in the first quarter of 2022.

Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 4, 2022
Roivant Sciences, Virology, Journal of Clinical Oncology, Coronavirus, Annual general meeting, COVID-19, Arbutus, VBR, HBsAg, Technology transfer, RNA interference, Degenerative disease, RNA, HBV, ASCO, Patient, Company, ALT, Association, Nasdaq, Safety, Society, American Society of Clinical Oncology, Assembly, Journal, ILC, EASL, Investment, European Association for the Study of the Liver, Antibody, Research, Therapy, Achievement, GLOBE, Severe acute respiratory syndrome coronavirus 2, Â, NA, CFBV, PD-L1, Clinical trial, Vaccine, Pharmaceutical industry, Tutoring, Liver, IND, Vaccitech

WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.

Key Points: 
  • WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its second quarter 2022 financial results and provides corporate updates.
  • Finally, our financial position is strong with a projected cash runway into the second quarter of 2024.
  • The Company is on-track to report initial data in the second half of 2022.
  • The Company will provide an update with respect to the status and timing of this clinical trial in the second half of 2022.

Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Retrieved on: 
Thursday, July 21, 2022
Nasdaq, Arbutus, Therapy, Severe acute respiratory syndrome coronavirus 2, Virology, PD, Program, Drug discovery, Patient, ID, Hepatitis B virus, RNA interference, RNA, Immune system, HBV, Coronavirus, Degenerative disease, Video game, Vaccine

Alternatively, you may access a replay of the conference call by calling (800) 770-2030 or (609) 800-9909, and reference conference ID: 5109143.

Key Points: 
  • Alternatively, you may access a replay of the conference call by calling (800) 770-2030 or (609) 800-9909, and reference conference ID: 5109143.
  • Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.
  • We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening.
  • We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2).

Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor

Retrieved on: 
Wednesday, July 20, 2022
Goal, Patient, Conditional sentence, Death, N-Acetylgalactosamine, Severe acute respiratory syndrome coronavirus 2, CFBV, HBsAg, GLOBE, HBeAg, Forward-looking statement, World, Cornerstone, PD, Cirrhosis, Drug discovery, Hepatitis B virus, Securities Act of 1933, Securities Exchange Act of 1934, Risk, RNA interference, Patent, Immune system, COVID-19, Safety, World Health Organization, NA, Assembly, Virology, Hepatitis B, Clinical trial, Liver cancer, VBR, Coronavirus, Nasdaq, Pharmacokinetics, Therapy, Membrane protein, HBV, Hepatocyte, Annual report, Program, Drug Quality and Security Act, Antigen, RNA, Vaccine, Degenerative disease, Pharmaceutical industry, Arbutus

WARMINSTER, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that while its partner, Assembly Biosciences, has decided to discontinue development of its investigational hepatitis B virus core inhibitor candidate vebicorvir (VBR), it plans, in consultation with Assembly Biosciences, to continue dosing patients in the Phase 2a triple combination clinical trial evaluating its proprietary RNAi therapeutic, AB-729, VBR and nucleos(t)ide analogue (NA) therapy for the treatment of patients with chronic HBV infection (cHBV). Preliminary data from the trial are expected in the second half of 2022.

Key Points: 
  • We intend, in collaboration with Assembly, to continue the clinical trial in order to fully and accurately assess the results.
  • The results from this trial coupled with the additional data we anticipate collecting from our capsid inhibitor program will help inform our go-forward combination strategy in the development of cHBV treatments."
  • AB-729 targets hepatocytes using Arbutus novel covalently conjugated N-Acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery.
  • Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Retrieved on: 
Wednesday, July 20, 2022
Virus, CFBV, GLOBE, IFNAR, U.S. Securities and Exchange Commission, Doctor of Philosophy, Arbutus, SEC, Research, C1-inhibitor, Hepatitis B virus, Securities Act of 1933, Workforce, Securities Exchange Act of 1934, Degenerative disease, RNA interference, COVID-19, Safety, AO, HDV, Assembly, Virology, Webcast, CccDNA, Review, VBR, Â, MD, Patient, Pharmacokinetics, SVP, Sumathi Best Television Current Reporting Award, Therapy, Annual report, Program, Maritime Transportation Security Act of 2002, HBV, Pharmaceutical industry, Fine chemical, Vaccine, Management

SOUTH SAN FRANCISCO, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that it is discontinuing further development of its first-generation core inhibitor, vebicorvir (VBR), as it prioritizes clinical development of its next-generation core inhibitors, ABI-H3733 (3733) and ABI-4334 (4334), and advances its research pipeline. Assembly Bio will restructure the organization and reduce its workforce to align with these strategic goals.

Key Points: 
  • Assembly Bio will restructure the organization and reduce its workforce to align with these strategic goals.
  • Assembly Biosciences will discontinue clinical development of its first-generation investigational core inhibitor, VBR, based on review of interim on-treatment efficacy from the two ongoing VBR triple combination studies.
  • Luisa Stamm, MD, PhD, the current Assembly Bio chief medical officer, will leave the company at the end of this month.
  • Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022

Retrieved on: 
Wednesday, June 8, 2022
ILC, HBsAg, EASL, European Association for the Study of the Liver, Conference, NA, ET, Arbutus, Viral hepatitis, Viral, Nasdaq, Therapy, BST, 2021 Essex County Council election, GLOBE, Patient, Virology, Association, Degenerative disease, Pharmaceutical industry, Liver

WARMINSTER, Pa., June 07, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that seven abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 (ILC 2022) taking place June 22 - 26, 2022 in London, UK. The posters will be presented in the Viral hepatitis B/D therapy session on Saturday, June 25, 2022 between 9:00 am – 6:00 pm BST (4:00 am – 1:00 pm ET), and will include updated data where available.

Key Points: 
  • Arbutus will hold a conference call at 8:00 am ET on Monday, June 27, 2022, to discuss the new data being presented at EASL ILC.
  • Abstracts are available to EASL ILC 2022 conference attendees on the conference website at https://easl.eu/event/international-liver-congress-2022 .
  • The posters are expected to be made available to conference attendees at the start of the meeting on June 22, 2022.
  • A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus Annual Report on Form 10-K, Arbutus Quarterly Reports on Form 10-Q and Arbutus continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov.

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Retrieved on: 
Monday, June 6, 2022
Hepatocyte, Hepatitis B, Goal, N-Acetylgalactosamine, CFBV, Therapy, HBV, AstraZeneca, COVID-19, Immune system, Severe acute respiratory syndrome coronavirus 2, PD, Cancer, University, Immunotherapy, Liver cancer, Forward-looking statement, Hepatitis B virus, OUI, Securities Exchange Act of 1934, Cirrhosis, Securities Act of 1933, Antigen, Patient, Poxviridae, World, World Health Organization, Annual report, RNA interference, RNA, Conditional sentence, Vaccine, Virology, Degenerative disease, Oxford University Innovation, Coronavirus, Program, NA, Drug Quality and Security Act, MVA, Nasdaq, GLOBE, Risk, Drug discovery, ChAdOx1, Death, Membrane protein, Safety, Autoimmunity, Pharmaceutical industry, HBsAg, Vaccitech, Arbutus

WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the first patient dosed in a Phase 2a clinical trial. This trial will evaluate Arbutus’ RNAi therapeutic candidate, AB-729, in combination with Vaccitech’s T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NA) therapy for the treatment of patients with virologically-suppressed chronic HBV infection (cHBV).

Key Points: 
  • We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.
  • The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients.
  • Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA.
  • Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV).

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Retrieved on: 
Monday, June 6, 2022
Hepatocyte, Hepatitis B, Goal, N-Acetylgalactosamine, CFBV, Therapy, HBV, AstraZeneca, COVID-19, Immune system, Severe acute respiratory syndrome coronavirus 2, PD, Cancer, University, Immunotherapy, Liver cancer, Forward-looking statement, Hepatitis B virus, OUI, Securities Exchange Act of 1934, Cirrhosis, Securities Act of 1933, Antigen, Patient, Poxviridae, OXFORD, World, World Health Organization, Annual report, RNA interference, RNA, Conditional sentence, Vaccine, Virology, Degenerative disease, Oxford University Innovation, Coronavirus, Program, NA, Drug Quality and Security Act, MVA, Nasdaq, GLOBE, Risk, Drug discovery, ChAdOx1, Death, Membrane protein, Safety, Autoimmunity, Pharmaceutical industry, HBsAg, Vaccitech, Arbutus

We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.

Key Points: 
  • We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.
  • The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients.
  • Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA.
  • Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV).